OLEMA PHARMACEUTICALS INC (OLMA) Stock Price, Forecast & Analysis
NASDAQ:OLMA • US68062P1066
OLMA Key Statistics, Chart & Performance
The current stock price of OLMA is 23.505 USD. In the past month the price decreased by -6.61%. In the past year, price increased by 421.04%.
OLMA Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to OLMA. When comparing the yearly performance of all stocks, OLMA is one of the better performing stocks in the market, outperforming 98.78% of all stocks.
OLMA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OLMA. The financial health of OLMA is average, but there are quite some concerns on its profitability.
OLMA Financial Highlights
Over the last trailing twelve months OLMA reported a non-GAAP Earnings per Share(EPS) of -1.87. The EPS increased by 14.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.55% | ||
| ROE | -48.77% | ||
| Debt/Equity | 0.01 |
OLMA Forecast & Estimates
18 analysts have analysed OLMA and the average price target is 46.73 USD. This implies a price increase of 98.83% is expected in the next year compared to the current price of 23.505.
OLMA Ownership
OLMA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.07 | 414.026B | ||
| AMGN | AMGEN INC | 16.74 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.55 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.3 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.81 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.81 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.1 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.9 | 22.521B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OLMA
Company Profile
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
Company Info
OLEMA PHARMACEUTICALS INC
780 Brannan Street
San Francisco CALIFORNIA 94107 US
CEO: Sean Bohen
Employees: 122
Phone: 13026587581
OLEMA PHARMACEUTICALS INC / OLMA FAQ
What does OLEMA PHARMACEUTICALS INC do?
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. The company is headquartered in San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2020-11-19. The firm is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. The company is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. The company is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.
What is the stock price of OLEMA PHARMACEUTICALS INC today?
The current stock price of OLMA is 23.505 USD. The price decreased by -2.14% in the last trading session.
Does OLEMA PHARMACEUTICALS INC pay dividends?
OLMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of OLMA stock?
OLMA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the number of employees for OLEMA PHARMACEUTICALS INC?
OLEMA PHARMACEUTICALS INC (OLMA) currently has 122 employees.
What is the next earnings date for OLMA stock?
OLEMA PHARMACEUTICALS INC (OLMA) will report earnings on 2026-03-16, after the market close.